NCT03334695View on ClinicalTrials.gov

An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

October 16, 2017

Primary Completion Date

July 10, 2018

Study Completion Date

November 27, 2018

Conditions
Healthy
Interventions
BIOLOGICAL

Ad26.RSV.preF

Ad26.RSV.preF will be administered as intramuscular injection at a dose of 1\*10\^11 vp in single-use vials.

DRUG

Placebo

Placebo will be administered as sterile 0.9% saline for injection.

Trial Locations (1)

E1 2AX

hVIVO Services Limited, London

All Listed Sponsors
lead

Janssen Vaccines & Prevention B.V.

INDUSTRY

NCT03334695 - An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old Adults | Biotech Hunter | Biotech Hunter